Dr Reddy's Laboratories Ltd-ADR
Gesloten
SectorGezondheidszorg
13.24 1.46
Overzicht
Wijziging aandelenprijs
24u
Min
13.02
Max
13.33
Inkomsten | -9.7B 2.2B |
|---|---|
Verkoop | -11B 76B |
K/W Sectorgemiddelde | 24.556 49.888 |
Dividendrendement | 0.63 |
Winstmarge | 2.928 |
Werknemers | 27,527 |
EBITDA | -13B 6.1B |
Dividendrendement Sectorgemiddelde | 0.63% 2.38% |
|---|
Marktkapitalisatie | 68M 11B |
|---|---|
Vorige openingsprijs | 11.78 |
Vorige sluitingsprijs | 13.24 |
Nieuwssentiment
By Acuity
50%
50%
155 / 344 Rangschikking in Healthcare
Dr Reddy's Laboratories Ltd-ADR Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Dr Reddy's Laboratories Ltd-ADR Prognose
Sentiment
By Acuity
155 / 344 Rangschikking in Gezondheidszorg
Nieuwssentiment
Neutral
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Gemiddelde
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Dr Reddy's Laboratories Ltd-ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.